Compare Novavax Inc (NVAX) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Vital Farms Inc — how do they compare? Novavax Inc trades at $12.57 (market cap $1.82B), while Vital Farms Inc trades at $9.31 (market cap $405.27M). The key difference: Novavax Inc is far larger — about 4.5× Vital Farms Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Vital Farms Inc for 14 Days on average.
| NVAX | VITL | |
|---|---|---|
Market Cap | $1.82B | $405.27M |
Volume | 6,198,505 | 1,810,837 |
Sector | Health | Consumer Staples |
52-Week High | $12.56 | $43.68 |
52-Week Low | $6.22 | $8.28 |
Typical Hold Time | 59 Days | 14 Days |
Enterprise Value | $1.39B | $492.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
Vital Farms (VITL) trades at $9.45, up 2.27% today, amid a challenging fundamental backdrop. The stock exhibits a bearish technical trend, with recent earnings showing significant pressure on profitability. Revenue for 2025 was $759.44M with a net income of $66.28M, but 2026 projections indicate a sharp decline in net income to near breakeven. Recent news highlights strategic review discussions and institutional investment activity, contributing to volatile price action.
The outlook is mixed; analyst consensus is bullish with a $13.11 price target, but near-term risks from egg pricing pressure and weak profitability metrics pose challenges. Investment opportunity hinges on successful execution of strategic options and margin recovery, while downside risks include sustained industry oversupply and cash flow constraints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
